Mucosal patches and methods of use thereof

A flexible electrospun patch with an impermeable layer addresses the inefficiencies of conventional treatments for mucosal conditions by providing controlled, prolonged delivery of active agents to sensitive areas, improving treatment efficacy and comfort.

JP2024542227AInactive Publication Date: 2024-11-13アフリックス デベロップメント アーエス
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529782
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-23
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Conventional therapeutic compositions for mucosal conditions, such as lichen sclerosus, are ineffective and require frequent reapplication, leading to discomfort and prolonged treatment periods due to inadequate delivery and adherence to sensitive areas.

Method used

A flexible electrospun patch with an impermeable layer, containing an active agent, is designed for unidirectional delivery to mucosal surfaces, providing controlled release and prolonged adherence to treat conditions like vulvar lichen sclerosus.

Benefits of technology

The patch offers therapeutically effective active agent delivery for at least 2 hours, enhancing treatment efficacy and comfort by adhering to sensitive areas without frequent reapplication.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542227000001_ABST
    Figure 2024542227000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to a flexible electrospun patch comprising an electrospun active agent-containing layer and a hydrophobic layer.When applied to a target site, the flexible patch adheres for a sufficient time to release a therapeutically effective amount of active agent for treating various conditions, including vulvar conditions such as vulvar lichen sclerosus.Combined with high encapsulation efficiency and fast release rate of active agent, the disclosed patch can controllably release active agent to affected areas at a clinically effective rate in various embodiments.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 282,548, filed November 23, 2021, which is incorporated herein by reference in its entirety. [Background technology]

[0002] background Mucosal conditions are often difficult to treat with conventional therapeutic compositions and dressings. For example, lichen sclerosus (LS) is a chronic inflammatory skin disease that most often affects the genital area (e.g., vulva) and perianal area. Typical symptoms include skin lesions and itching and pain. Therapeutic intervention, usually in the form of topical creams and ointments, is required for improvement. However, despite these treatments, the condition can persist for years and recurrence is common.

[0003] Thus, there is a need in the art for new therapeutic compositions that provide more effective treatment of mucosal conditions, including inflammatory skin conditions such as vulvar lichen sclerosus. Summary of the Invention [Means for solving the problem]

[0004] Abstract To address the above-mentioned problems, the present disclosure provides flexible, optionally active agent-containing electrospun patches with an impermeable layer that are designed to adhere to the target site and, if containing an active agent, provide localized, unidirectional delivery of the active agent to the target site, e.g., mucosa or skin. These flexible patches have been found to be easy to apply and comfortable to wear, and adhere to the target area for extended periods of time. Combined with high encapsulation efficiency and fast release rate of the active agent, the disclosed patches can controllably release the active agent to the affected area at a clinically effective rate in various embodiments.

[0005] Thus, in some embodiments, the patches disclosed herein are useful in treating a variety of diseases and conditions, including chronic inflammatory skin conditions such as vulvar lichen sclerosus.

[0006] In one aspect, the present disclosure provides a patch with improved flexibility for treating a disease or condition of the vulva comprising (a) an electrospun fiber layer comprising electrospun fibers comprising one or more polymers and a therapeutically effective amount of an active agent, and (b) an impermeable layer, wherein after application to a patient in need thereof, the patch provides a therapeutically effective amount of the active agent for at least about 2 hours, and the stiffness of the patch is from about 250 mN / mm to about 450 mN / mm, as determined by a three-point bending test.

[0007] In one aspect, the present disclosure provides a patch with improved flexibility for treating a disease or condition of the oral cavity comprising: (a) an electrospun fiber layer comprising electrospun fibers comprising one or more polymers and a therapeutically effective amount of an active agent; and (b) an impermeable layer, wherein after application to a patient in need thereof, the patch provides a therapeutically effective amount of the active agent for at least about 2 hours, and the stiffness of the patch is from about 250 mN / mm to about 450 mN / mm, as determined by a three-point bending test.

[0008] In some embodiments, at least one of the electrospun fiber and the impermeable layer further comprises a plasticizer. In some embodiments, the electrospun fiber further comprises a plasticizer. In some embodiments, the impermeable layer comprises a plasticizer.

[0009] In some embodiments, the plasticizer is selected from the group consisting of citrate esters, fatty acid esters, sebacate esters, phthalates, and glycol derivatives.In some embodiments, the plasticizer is selected from the group consisting of triethyl citrate, acetyl triethyl citrate, tributyl citrate, butyl stearate, glycerol monostearate, stearyl alcohol, castor oil, mineral oil, diacetylated monoglyceride, dibutyl sebacate, diethyl phthalate, dibutyl phthalate, dioctyl phosphate, sorbitol, glycerol, triacetin, tributyrin, cellulose nitrate, polyethylene glycol, polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof.In some embodiments, the plasticizer is dibutyl sebacate.

[0010] In some embodiments, the plasticizer is present in an amount ranging from about 5.0% to about 30% by weight of the patch.

[0011] In some embodiments, the electrospun fibers include from about 1% to about 20% by weight of a plasticizer, hi some embodiments, the impermeable layer includes from about 1% to about 20% by weight of a plasticizer.

[0012] In some embodiments, the one or more polymers are selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, dextran, and gelatin.

[0013] In some embodiments, the one or more polymers are selected from the group consisting of polyvinylpyrrolidone (PVP), acrylate and acrylic acid copolymers, and mixtures thereof. In some embodiments, the one or more polymers are polyvinylpyrrolidone (PVP), ammonio methacrylate copolymer type B, or mixtures thereof. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer is about 0.8 to about 2. In some embodiments, the electrospun fiber layer further comprises a bioadhesive material. In some embodiments, the bioadhesive material is selected from the group consisting of dextran, polyethylene oxide (PEO), alginate, tragacanth, carrageenan, pectin, gelatin, guar, xanthan, gellan, methylcellulose, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose and its alkali salts, polymers of acrylic acid (PAA derivatives), chitosan, lectin, thiolated polymers, polyoxWSR, PAA-co-PEG (PEG is polyethylene glycol), and mixtures thereof. In some embodiments, the bioadhesive material is PEO. In some embodiments, the weight ratio of PVP:ammonio methacrylate copolymer B:PEO is about 2:1:1 to about 2:2.5:4.

[0014] In some embodiments, the electrospun fibrous layer has an areal density of less than about 125 grams per square meter (gsm). In some embodiments, the electrospun fibrous layer has an areal density of less than about 100 grams per square meter (gsm). In some embodiments, the electrospun fibrous layer has an areal density of less than about 75 gsm. In some embodiments, the electrospun fibrous layer has an areal density of between about 15 gsm and about 75 gsm. In some embodiments, the electrospun fibrous layer has an areal density greater than the impermeable layer.

[0015] In some embodiments, the impermeable layer comprises a hydrophobic polymer. In some embodiments, the hydrophobic polymer is selected from the group consisting of polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone) (PCL), carbosan, or polysoftan. In some embodiments, the hydrophobic polymer is PCL.

[0016] In some embodiments, the disease or condition of the vulva is selected from the group consisting of vulvar lichen sclerosus, vulvar lichen planus, vulvar psoriasis, vulvar skin disease, and vulvar lichen simplex chronicus. In some embodiments, the disease or condition of the vulva is vulvar lichen sclerosus.

[0017] In some embodiments, the active agent is an anti-inflammatory agent or an immunosuppressant. In some embodiments, the anti-inflammatory agent or the immunosuppressant is a corticosteroid. In some embodiments, the corticosteroid is selected from the group consisting of diflorasone diacetate, betamethasone dipropionate, mometasone furoate, and clobetasol propionate. In some embodiments, the corticosteroid is mometasone furoate. In some embodiments, the immunosuppressant is a calcineurin inhibitor. In some embodiments, the calcineurin inhibitor is cyclosporine, tacrolimus, or pimecrolimus.

[0018] In some embodiments, the electrospun fibrous layer comprises about 0.01% to about 50.0% (wt / wt%) of an active agent. In some embodiments, the electrospun fibrous layer comprises about 1.0% to about 10.0% (wt / wt%) of an active agent.

[0019] In some embodiments, at least about 50% of the active agent is released from the electrospun fiber layer within about 30 minutes after application, hi some embodiments, complete release of the active agent from the electrospun fiber layer is achieved within about 2-3 hours after application.

[0020] In some aspects, the present disclosure provides a method of treating a disease or condition of the oral cavity in a patient in need thereof, the method comprising applying a patch disclosed herein to the oral mucosa of a patient in need thereof.

[0021] In some aspects, the present disclosure provides a method of treating a disease or condition of the vulva in a patient in need thereof, the method comprising applying a patch as disclosed herein to a vulvar lesion in a patient in need thereof.

[0022] In some aspects, the present disclosure provides a method of treating vulvar lichen sclerosus in a patient in need thereof, the method comprising applying a patch disclosed herein to a VLS lesion in a patient in need thereof.

[0023] In some embodiments, the patch is applied once daily, twice daily, three times daily, or four times daily. In some embodiments, the patch is applied once daily. [Brief description of the drawings]

[0024] [Figure 1] Figure 1 shows the amount of mometasone recovered (as a percentage of the mass of the electrospun fiber material) from samples of electrospun fibers in methanol: Sample 1: 0.1 wt% mometasone; Sample 2: 0.01 wt% mometasone; Sample 3: 0.1 wt% mometasone / 7.35 wt% dibutyl sebacate; Sample 4: 0.01 wt% mometasone / 7.35 wt% dibutyl sebacate.

[0025] [Diagram 2] FIG. 2 shows the amount of mometasone released from electrospun fibers (samples 1-4) over 3 hours in phosphate buffered saline as a percentage of the electrospun fiber mass (FIG. 2A) and as the amount of mometasone released as a percentage of the total amount of mometasone released (FIG. 2B).

[0026] [Figure 3A]FIG. 3A provides a graph comparing the force applied to bioadhesive electrospun monolayer compositions with (Modified) and without (Rivelin) dibutyl sebacate plasticizer.

[0027] [Figure 3B] FIG. 3B provides a graph comparing the force applied to bioadhesive electrospun bilayer compositions with (Modified) and without (Rivelin) dibutyl sebacate plasticizer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] Detailed Description For convenience, certain terms employed in the specification, examples, and claims are collected here. Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0029] Throughout this disclosure, various patents, patent applications, and publications are referenced. The disclosures of these patents, patent applications, and publications in their entireties are incorporated by reference into this disclosure for all purposes to more fully describe the state of the art known to those skilled in the art as of the date of this disclosure. In the event of any inconsistency between the cited patents, patent applications, and publications and this disclosure, this disclosure shall govern.

[0030] The term "about", when directly preceding a numerical value, refers to a range (e.g., plus or minus 10% of the value). For example, "about 50" can refer to 45 to 55, "about 25,000" can refer to 22,500 to 27,500, etc., unless the context of this disclosure dictates otherwise or contradicts such an interpretation. For example, in a list of numerical values ​​such as "about 49, about 50, about 55, ...", "about 50" refers to a range that spans less than half the interval between the preceding and succeeding values, e.g., a range from greater than 49.5 to less than 52.5. Furthermore, the phrases "less than about a value" or "greater than about a value" should be understood in light of the definition of the term "about" provided herein. Similarly, the term "about", when preceding a series of numerical values ​​or a range of values ​​(e.g., "about 10, 20, 30", or "about 10 to 30"), refers to all values ​​in the series, or to the end points of the range, respectively.

[0031] In the present specification and claims, the term "and / or" as used herein should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctive in some cases and disjunctive in other cases. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so conjoined. Other elements other than the elements specifically identified by the "and / or" clause may optionally be present, whether related or unrelated to the elements specifically identified. That is, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may in one embodiment mean only A (optionally including elements other than B), in another embodiment mean only B (optionally including elements other than A), in yet another embodiment may mean both A and B (optionally including other elements), and so forth.

[0032] "Optionally" or "as needed" means that the subsequently described element, event, or circumstance may or may not occur, and that the description includes instances when said event, element, or circumstance occurs and instances when it does not occur.

[0033] As used herein, a "patient" includes a vertebrate, more specifically a mammal (e.g., a human, horse, pig, rabbit, dog, sheep, goat, non-human primate, cow, cat, guinea pig, or rodent), fish, bird, or reptile or amphibian. In some embodiments, the patient is a human patient. Unless otherwise specified, the term "patient" does not denote a particular age or sex. In some embodiments, the patient may be an elderly patient, a pediatric patient, a teenage patient, a young adult patient, or a middle-aged patient. In some embodiments, the patient is less than about 18 years of age. In some embodiments, the patient is at least about 18 years of age. In some embodiments, the patient is about 5-10, about 10-15, about 15-20, about 20-25, about 25-30, about 30-35, about 35-40, about 40-45, about 45-50, about 50-55, about 55-60, about 60-65, about 65-70, about 70-75, about 75-80, about 85-90, about 90-95, or about 95-100 years of age. In some embodiments, the patient is a male patient. In some embodiments, the patient is a female patient. In some embodiments, the patient has, has been diagnosed with, or is considered at risk for developing a disease or condition of the vulva, such as vulvar lichen sclerosus.

[0034] As used herein, the term "impermeable layer" or "impermeable backing layer" refers to a coating or barrier layer in a layered patch structure that prevents or substantially limits the passage of water through that layer. An impermeable layer can also prevent or substantially limit the passage of an active ingredient through that layer.

[0035] As used herein, the term "oligomeric plasticizer" refers to a polymeric plasticizer that has a lower molecular weight than plasticizers that are considered "polymeric." Typically, oligomeric plasticizers have up to 100 repeat units.

[0036] As used herein, the term "polymeric plasticizer" refers to a polymeric plasticizer having more than 100 repeat units. In some embodiments, the polymeric plasticizer of the present disclosure has a molecular weight (MW) of up to about 100,000 Da. In some embodiments, the polymeric plasticizer has a molecular weight of up to about 35,000 Da. In some embodiments, the polymeric plasticizer has a molecular weight of about 2,000 Da to about 100,000 Da. In some embodiments, the polymeric plasticizer has a molecular weight of about 2,000 Da to about 35,000 Da.

[0037] As used herein, the term "treat" in reference to a patient means improving at least one symptom of the patient's disorder. Treating may be curing, improving, or at least partially ameliorating the disorder. As used herein, the term "therapeutic effect" refers to the desired or beneficial effect provided by the method and / or composition. For example, a method for treating a disclosed disease or condition provides a therapeutic effect if the method reduces at least one symptom of the disease or condition in a patient.

[0038] As used herein, the term "prevent" in reference to a patient means reducing or eliminating the onset of symptoms or complications of a disease, condition, or disorder. In some embodiments, symptoms or complications are reduced or eliminated in a patient who is predisposed to the disease, condition, or disorder. The patch of the present disclosure can prevent or treat such diseases, conditions, or disorders.

[0039] All documents cited herein are incorporated by reference in their entirety for all purposes.

[0040] Inflammatory anogenital skin conditions such as lichen sclerosus of the vulva, penis, and perianal area can result in painful lesions and significant discomfort that can cause permanent damage if left untreated. Although topical ointments and creams are commonly prescribed as treatments, these preparations are often inconvenient to apply to the affected area and may need to be reapplied once or more throughout the day. This is particularly problematic because conditions such as lichen sclerosus tend to recur, meaning that extended periods of repeated treatments may be necessary.

[0041] Flexible, optionally containing active agents, patches may provide an alternative option for treating inflammatory anogenital skin conditions.However, current oral patches (see International Publication Nos. WO2015 / 189212, WO2017 / 085264, WO2018 / 133910, and WO2018 / 133909; US Patent No. 10,052,291, and US Publication Nos. 2019 / 0254985, 2019 / 0254986, and 2019 / 0351662, which describe highly mucoadhesive oral patches that adhere to mucosal surfaces and deliver active agents, such as anesthetic lidocaine or steroid clobetasol propionate, and are hereby incorporated by reference in their entirety for all purposes) may not have suitable properties for delivering therapeutically effective amounts of active agents to the anogenital area.

[0042] To address this challenge, the present disclosure describes electrospun patches having increased flexibility (or lower stiffness), optionally including an active agent, that in various embodiments can provide localized, unidirectional delivery of a therapeutically effective amount of an active agent to the genital and perianal areas. As described herein, it has been discovered that the flexibility (or stiffness) of the patch can be adjusted by the addition of a plasticizer (described herein), by adjusting the composition of one or more polymers in the electrospun fibers, and / or by varying the areal density of the patch.

[0043] The disclosed flexible patch is found to adhere to the anogenital area of ​​the subject and is comfortable for a long period of time after application.These characteristics allow the disclosed patch to have a long residence time at the treatment site, which can be effective in treating inflammatory skin conditions (e.g., vulvar lichen planus) and other diseases that affect external genitalia and perianal area, especially when combined with high encapsulation efficiency and clinically useful release rate of active agent.

[0044] In some embodiments, the present disclosure provides a patch for treating a disease or condition comprising: (i) an electrospun fiber layer comprising electrospun fibers comprising (a) an active agent, (b) one or more hydrophilic polymers, (c) a bioadhesive, and (d) optionally a plasticizer; and (ii) a hydrophobic layer comprising (a) a hydrophobic polymer, and (b) optionally a plasticizer, wherein the patch provides a therapeutically effective amount of the active agent for at least about 2 hours after application to a lesion.

[0045] The flexibility of the disclosed patch (e.g., as measured by stiffness) can be determined by any method known in the art. In some embodiments, the flexibility of the disclosed patch is determined by a three-point bending test, which can be performed, for example, using a texture analyzer. An example of a suitable three-point bending test is described in Byun et al. The Effect of Calcium on the Cohesive Strength and Flexural Properties of Low-Methoxyl Pectin Biopolymers, Molecules, 2020, 25(1), 75, the subject matter of which is incorporated herein in its entirety for all purposes.

[0046] In some embodiments, the patch of the present disclosure has a stiffness of less than about 650 mN / mm, less than about 625 mN / mm, less than about 600 mN / mm, less than about 575 mN / mm, less than about 550 mN / mm, less than about 525 mN / mm, less than about 500 mN / mm, less than about 475 mN / mm, less than about 450 mN / mm, less than about 425 mN / mm, less than about 400 mN / mm, less than about 375 mN / mm, less than about 350 mN / mm, less than about 325 mN / mm, less than about 300 mN / mm, less than about 275 mN / mm, less than about 250 mN / mm, less than about 225 mN / mm, or less than about 200 mN / mm, as measured by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of less than about 500 mN / mm, as measured by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of less than about 450 mN / mm as measured by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of less than about 400 mN / mm as measured by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of about 200 mN / mm to about 650 mN / mm, for example, about 200 mN / mm, about 250 mN / mm, about 300 mN / mm, about 350 mN / mm, about 400 mN / mm, about 450 mN / mm, about 500 mN / mm, about 550 mN / mm, about 600 mN / mm, or about 650 mN / mm as determined by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of about 250 mN / mm to about 450 mN / mm as determined by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of about 300 mN / mm to about 400 mN / mm as determined by a three-point bending test. In some embodiments, the patch of the present disclosure has a stiffness of about 300 mN / mm to about 350 mN / mm as determined by a three-point bending test.

[0047] In some embodiments, the three-point bending test is performed on a patch having dimensions and shapes effective for treating the conditions disclosed herein. In some embodiments, the patch subjected to the three-point bending test is circular, semicircular, elliptical, semi-elliptical (i.e., half-moon), square, or rectangular. In some embodiments, the patch is semicircular or semi-elliptical. In some embodiments, the patch is semicircular. In some embodiments, the patch is semi-elliptical. In some embodiments, a rectangular patch having a width of about 2 cm to about 4 cm and a length of about 5 cm to about 10 cm is subjected to the three-point bending test. In some embodiments, a semi-elliptical patch having a width of about 2 cm to about 4 cm and a length of about 5 cm to about 10 cm is subjected to the three-point bending test.

[0048] In some embodiments, the present disclosure provides a patch for treating a disease or condition comprising: (a) an electrospun fiber layer comprising electrospun fibers comprising one or more polymers and a therapeutically effective amount of an active agent; and (b) an impermeable layer, wherein after application to a patient in need thereof, the patch provides a therapeutically effective amount of the active agent for at least about 2 hours, and the stiffness of the patch is about 250 mN / mm to about 450 mN / mm, as determined by a three-point bending test.

[0049] In some embodiments, the flexibility of the patch disclosed herein is determined by measuring the elasticity of the patch.As understood in the art, elasticity is a measure of the ability of a patch to absorb energy when elastically deformed and then release the energy upon unloading.In some embodiments, the elasticity percentage of the patch is about 10% to about 50%, for example about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%, as determined from a three-point bending test.

[0050] In some embodiments, the flexibility of the patch disclosed herein is determined by measuring its stress relaxation. As understood in the art, stress relaxation is the observed decrease in stress in response to a certain strain applied to a material. In some embodiments, stress relaxation refers to a decrease in the tendency of a material to return to its original shape when unloaded. In some embodiments, the stress relaxation of the patch is about 100g to about 500g, such as about 100g, about 125g, about 150g, about 175g, about 200g, about 225g, about 250g, about 275g, about 200g, about 325g, about 350g, about 375g, about 400g, about 425g, about 450g, about 475g, or about 500g, as determined from a three-point bending test.

[0051] In some embodiments, the flexibility of the patch disclosed herein is determined by measuring its burst strength.As understood in the art, burst strength refers to the vertical force required to break a material.In some embodiments, the burst strength of the patch is about 2kg to about 20kg, for example, about 2kg, about 4kg, about 6kg, about 8kg, about 10kg, about 12kg, about 14kg, about 16kg, about 18kg, or about 20kg, calculated from a three-point bending test.

[0052] In some embodiments, the hydrophobic layer comprises one or more plasticizers disclosed herein. In some embodiments, the electrospun fibers comprise one or more plasticizers disclosed herein.

[0053] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer type B, and PEO, the impermeable layer includes PCL, and the plasticizer is dibutyl sebacate.

[0054] The electrospun fibrous layer and the impermeable layer are joined to provide a patch using methods known to those skilled in the art, such as the methods disclosed in International Publication No. WO / 2018 / 133909.

[0055] The patch of the present disclosure can be used to treat any disease or condition disclosed herein. In some embodiments, the disease or condition is an inflammatory skin disease of the genital area and / or perianal area (i.e., anogenital area). In some embodiments, the disease or condition is a disease or condition of the vulva. In some embodiments, the disease or condition is vulvar lichen sclerosus, vulvar lichen planus, vulvar psoriasis, vulvar skin disease, and vulvar chronic lichen simplex. In some embodiments, the disease or condition is vulvar lichen sclerosus. In some embodiments, the disease or condition is male genital lichen sclerosus. In some embodiments, the disease or condition is penile lichen sclerosus (PLS). In some embodiments, the disease or condition is an oral disease or condition. In some embodiments, the disease or condition is an oral mucosal disease or condition. In some embodiments, the oral disease or condition is selected from the group consisting of recurrent aphthous stomatitis, oral lichen planus, pemphigoid, pemphigus, oral mucositis, and Behcet's disease.

[0056] In some embodiments, when the disease or condition is vulvar lichen sclerosus, the lesion is a VLS lesion. In some embodiments, when the disease or condition is penile lichen sclerosus, the lesion is a PLS lesion.

[0057] To provide effective treatment, the patch of the present disclosure adheres to the target site (e.g., vulva, glans penis, or perineum) for a period of time sufficient to provide (i.e., release) an effective amount of the therapeutically active agent. Thus, in some embodiments, the patch adheres to the target site for a period of time greater than 2 hours, greater than 4 hours, greater than 8 hours, greater than 12 hours, greater than 16 hours, greater than 24 hours, greater than 30 hours, greater than 36 hours, greater than 42 hours, or greater than 48 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 2 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 4 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 6 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 8 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 12 hours. In some embodiments, the patch adheres to the target site for a period of time of at least 24 hours.

[0058] Without being bound to any particular theory, the impermeable layer, e.g., a hydrophobic impermeable layer, protects the patch from saliva or other sources of moisture to prevent premature detachment of the patch from the application site (skin or mucosa) Additionally, the impermeable layer facilitates application of the patch to the target site by providing a non-adhesive surface that does not stick to fingers.

[0059] In some embodiments, the patch according to the present disclosure provides a therapeutically effective amount of the active agent for at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, or at least about 24 hours after application to a patient in need thereof. In some embodiments, the patch provides a therapeutically effective amount of the active agent for at least about 4 hours after application to a patient in need thereof. In some embodiments, the patch provides a therapeutically effective amount of the active agent for at least about 8 hours after application to a patient in need thereof. In some embodiments, the patch provides a therapeutically effective amount of the active agent for at least about 12 hours after application to a patient in need thereof.

[0060] In some embodiments, a patch according to the present disclosure is applied to a patient in need thereof (e.g., to a patient's diseased area, including but not limited to the vulva, glans penis, and perineum) once a day, twice a day (bid), three times a day (tid), or four times a day (qid). In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) once a day. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) twice a day. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) three times a day. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) four times a day. In other embodiments, the patch is applied to a patient in need thereof as needed.

[0061] In some embodiments, a patch according to the present disclosure is applied to a patient in need thereof (e.g., to a patient's diseased area, including but not limited to the vulva, glans penis, and perineum) once a day for a period of about 2-8 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) twice a day for a period of about 2-8 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) three times a day for a period of about 2-8 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) four times a day for a period of about 2-8 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) once a day for a period of about 2-4 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., to a patient's diseased area) twice a day for a period of about 2-4 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) three times a day for a period of about 2-4 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) four times a day for a period of about 2-4 weeks. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) once a day for at least one month. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) twice a day for at least one month. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) three times a day for a period of at least one month. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) four times a day for a period of at least one month. In some embodiments, the patch is applied to a patient in need thereof (e.g., at the patient's disease site) once a day for at least one week. In some embodiments, the patch is applied to a patient in need thereof (e.g., to the patient's diseased area) twice a day for at least one week. In some embodiments, the patch is applied to a patient in need thereof (e.g., to the patient's diseased area) three times a day for a period of at least one week.In some embodiments, the patch is applied to a patient in need thereof (eg, to the patient's affected area) four times daily for a period of at least one week.

[0062] The flexibility of the patch disclosed herein can be adjusted to improve comfort and adhesion to disease sites, such as the vulva, perineum, or glans penis. In some embodiments, the flexibility of the patch is adjusted by modifying the thickness of the patch, including the electrospun layer and the impermeable layer. In some embodiments, for a patch having the same or substantially similar composition, reducing the thickness of the patch results in increased flexibility of the patch. In some embodiments, the average thickness of the patch before application is less than about 1 mm, less than about 0.8 mm, less than about 0.6 mm, or less than about 0.3 mm. In some embodiments, the average thickness of the patch before application is less than about 1 mm. In some embodiments, the average thickness of the patch before application is less than about 0.6 mm. In some embodiments, the average thickness of the patch before application is less than about 0.3 mm.

[0063] The patch of the present disclosure may be of any shape and size suitable for effective treatment of affected skin or tissue. In some embodiments, the patch of the present disclosure is circular, semicircular, elliptical, semi-elliptical (i.e., half-moon), square, or rectangular. In some embodiments, the patch is semicircular or semi-elliptical. In some embodiments, the patch is semicircular. In some embodiments, the patch is semi-elliptical. In some embodiments, the semi-elliptical patch is about 2 cm to about 4 cm wide and about 5 cm to about 10 cm long. Electrospun fiber layer

[0064] As used in this disclosure, the term "electrospun fibers" includes fibers obtained by processes involving static electricity. These processes, referred to in the art as electrohydrodynamic (EHD) processes, include electrospinning, coaxial electrospinning, coaxial electrospraying, emulsion electrospinning, and others. Any such process can be used to prepare the fibers of the present disclosure. Thus, the term "electrospun fibers" is not limited to fibers obtained by electrospinning, but instead refers to fibers obtained by electrohydrodynamic processes known in the art.

[0065] In some embodiments, the electrospun fibers or fiber layers of the patches of the present disclosure comprise from about 0.01% to about 50.0% (wt / wt%) of an active agent, such as about 0.01%, about 0.1%, about 0.5%, about 1%, about 2.5%, about 5%, about 7.5%, about 10%, 12.5%, about 15%, about 17.5%, about 20%, about 22.5%, about 25%, about 27.5%, about 30%, about 32.5%, about 35%, about 37.5%, about 40%, 42.5%, about 45%, about 47.5%, or about 50%, including all ranges and values ​​therebetween. In some embodiments, the electrospun fibers or fiber layers comprise from about 1.0% to about 10.0% (wt / wt%) of an active agent. In some embodiments, the electrospun fiber or fiber layer comprises about 1.0% to about 5.0% (wt / wt%) therapeutic polypeptide.

[0066] Generally, the electrospun fibers of the present disclosure are provided in a layer that adheres to the surface when applied to the skin, mucosa, or moist internal surfaces of a living organism. In some embodiments, the active agent (e.g., an anti-inflammatory and / or immunosuppressant active agent) can be uniformly distributed within the electrospun fiber, resulting in a constant concentration of the active drug substance per surface area of ​​the layer, and the dose of the active drug substance can be easily determined using the measured area of ​​the layer.

[0067] In some embodiments, the electrospun fiber layer of the present disclosure has an areal density of less than about 150 grams per square meter (gsm), less than about 140 gsm, less than about 125 gsm, less than about 115 gsm, less than about 105 gsm, less than about 95 gsm, less than about 90 gsm, less than about 85 gsm, less than about 80 gsm, less than about 75 gsm, less than about 70 gsm, less than about 65 gsm, less than about 60 gsm, less than about 55 gsm, less than about 50 gsm, less than about 45 gsm, less than about 40 gsm, less than about 35 gsm, less than about 30 gsm, less than about 25 gsm, less than about 20 gsm, less than about 15 gsm, less than about 10 gsm, or less than about 5 gsm, including all ranges and values ​​therebetween. In some embodiments, the electrospun fiber layer has an areal density of less than about 150 gsm. In some embodiments, the electrospun fiber layer has an areal density of less than about 125 gsm. In some embodiments, the electrospun fibrous layer has an areal density of less than about 100 gsm. In some embodiments, the electrospun fibrous layer has an areal density of less than about 75 gsm. In some embodiments, the electrospun fibrous layer has an areal density of less than about 50 gsm. In some embodiments, the electrospun fibrous layer has an areal density of less than about 25 gsm. In some embodiments, the electrospun fibrous layer has an areal density of less than about 15 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 10 gsm to about 100 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 15 gsm to about 75 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 15 gsm to about 50 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 15 gsm to about 30 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 15 gsm to about 20 gsm. In some embodiments, the electrospun fibrous layer has an areal density of about 17 gsm. In some embodiments, the reduced areal density of the electrospun fiber layer results in increased flexibility of the patch. In some embodiments, the increased flexibility patch is more comfortable after application to the treatment area of ​​the subject in need thereof. In some embodiments, the increased flexibility patch adheres to the anogenital area for a longer period of time compared to a less flexible patch.

[0068] In some embodiments, the electrospun fibers of the present disclosure comprise one or more polymers, a therapeutically effective amount of an active agent, and optionally a plasticizer, each of which is described in more detail below.

[0069] In some embodiments, the electrospun fibers of the present disclosure include one or more polymers, hi some embodiments, the one or more polymers are hydrophilic polymers, hydrophobic polymers, or mixtures thereof.

[0070] In some embodiments, the electrospun fibers of the present disclosure comprise one or more polymers selected from the group consisting of dextran, polyethylene oxide, alginate, tragacanth, carrageenan, pectin, gelatin, guar, xanthan, gellan, fibronectin, collagen, hyaluronic acid, chitosan, cellulosic polymers such as methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose, cellulose acetate, carboxymethylcellulose and its alkali salts, polymers of acrylic acid (PAA derivatives), chitosan, lectin, thiolated polymers, polyoxWSR, PAA-co-PEG (PEG is polyethylene glycol), polylactic acid, polyglycolic acid, poly(butylene succinate), and mixtures thereof. In some embodiments, the electrospun fibers comprise one or more polymers selected from the group consisting of polyethylene-co-vinyl acetate, ethylcellulose, poly(caprolactone) (PCL), carbosan, or polysoftan.

[0071] In some embodiments, the electrospun fibers of the present disclosure comprise one or more polymers selected from the group consisting of polyvinylpyrrolidone (PVP), acrylate and acrylic acid copolymers (e.g., Eudragit®), ethyl cellulose (EC), hydroxypropyl cellulose (HPC), polyvinyl alcohol, carboxymethyl cellulose, and mixtures thereof. In some embodiments, the one or more polymers are selected from polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), and mixtures thereof. In some embodiments, the one or more polymers are polyvinyl alcohol or carboxymethyl cellulose.

[0072] In some embodiments, the electrospun fibers of the present disclosure comprise one or more polymers selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, polycaprolactone (PCL), dextran, and gelatin. In some embodiments, the electrospun fibers comprise one or more polymers selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, dextran, and gelatin.

[0073] In some embodiments, the electrospun fibers of the present disclosure comprise one or more polymers selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, dextran, and gelatin.

[0074] In some embodiments, the one or more polymers are selected from the group consisting of polyvinylpyrrolidone (PVP), acrylate and acrylic acid copolymers, and mixtures thereof.

[0075] In some embodiments, the one or more polymers are polyvinylpyrrolidone (PVP), ammonio methacrylate copolymer type B, or a mixture thereof.

[0076] In some embodiments, the one or more polymers are (a) polyvinylpyrrolidone and ammonio methacrylate copolymer, (b) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene glycol, (c) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene oxide, (d) polyvinylpyrrolidone, ammonio methacrylate copolymer, and dextran, (e) polyvinylpyrrolidone and gelatin, (f) polyvinylpyrrolidone, ammonio methacrylate copolymer, and gelatin, (g) polyvinylpyrrolidone and polyacrylate. (h) polyvinylpyrrolidone and sodium polyacrylate, (i) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyacrylate, (j) polyvinylpyrrolidone, ammonio methacrylate copolymer, and sodium polyacrylate, (k) polyvinylpyrrolidone and polyvinyl alcohol, (l) polyvinylpyrrolidone and polyethylene glycol, (m) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyvinyl alcohol, (n) polyvinylpyrrolidone and polyethylene oxide, or (o) polyvinylpyrrolidone and dextran.

[0077] In some embodiments, the one or more polymers include polyvinylpyrrolidone and ammonio methacrylate copolymer. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer in the electrospun fibers is about 0.1 to about 10, including all ranges and values ​​therebetween, including about 0.1, about 0.25, about 0.5, about 0.75, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer is about 0.5 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer is about 0.5 to about 1.5.

[0078] In some embodiments, the one or more polymers include polyvinylpyrrolidone and polyethylene glycol. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene glycol in the electrospun fibers is about 0.15 to about 10, including all ranges and values ​​therebetween, such as 0.15, about 0.5, about 0.75, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene glycol is about 0.25 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene glycol is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene glycol is about 0.5 to about 1.5.

[0079] In some embodiments, the one or more polymers include polyvinylpyrrolidone and polyethylene oxide. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene oxide in the electrospun fibers is about 0.3 to about 10, including all ranges and values ​​therebetween, including about 0.3, about 0.5, about 0.75, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene oxide is about 0.3 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene oxide is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyethylene oxide is about 0.5 to about 1.5.

[0080] In some embodiments, the one or more polymers include polyvinylpyrrolidone and dextran. In some embodiments, the weight ratio of polyvinylpyrrolidone to dextran in the electrospun fibers is about 0.3 to about 10, such as about 0.3, about 0.5, about 0.75, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10, including all ranges and values ​​therebetween. In some embodiments, the weight ratio of polyvinylpyrrolidone to dextran is about 0.3 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to dextran is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to dextran is about 0.5 to about 1.5.

[0081] In some embodiments, the one or more polymers include polyvinylpyrrolidone and gelatin. In some embodiments, the weight ratio of polyvinylpyrrolidone to gelatin in the electrospun fibers is about 0.6 to about 10, such as about 0.6, about 0.8, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10, including all ranges and values ​​therebetween. In some embodiments, the weight ratio of polyvinylpyrrolidone to gelatin is about 0.6 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to gelatin is about 1 to about 3. In some embodiments, the weight ratio of polyvinylpyrrolidone to gelatin is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to gelatin is about 0.5 to about 1.5.

[0082] In some embodiments, the one or more polymers include polyvinylpyrrolidone and polyvinyl alcohol. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyvinyl alcohol in the electrospun fibers is about 0.5 to about 10, such as about 0.5, about 0.75, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10, including all ranges and values ​​therebetween. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyvinyl alcohol is about 0.5 to about 5. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyvinyl alcohol is about 1 to about 3. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyvinyl alcohol is about 0.8 to about 2. In some embodiments, the weight ratio of polyvinylpyrrolidone to polyvinyl alcohol is about 0.5 to about 1.5.

[0083] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene glycol. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer to polyethylene glycol in the electrospun fibers is about 1:0.5:0.1 to about 1:2:6, including all ranges and values ​​therebetween.

[0084] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene oxide. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer to polyethylene oxide in the electrospun fibers is about 2:1:1 to about 2:2.5:4, including all ranges and values ​​therebetween.

[0085] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer, and dextran. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer to dextran in the electrospun fibers is about 1:0.5:0.1 to about 1:2:3, including all ranges and values ​​therebetween.

[0086] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer, and gelatin. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer to gelatin in the electrospun fibers is about 1:0.5:0.1 to about 1:2:1.5, including all ranges and values ​​therebetween.

[0087] In some embodiments, the one or more polymers include polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyvinyl alcohol. In some embodiments, the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer to polyvinyl alcohol in the electrospun fibers is about 1:0.5:0.1 to about 1:2:2, including all ranges and values ​​therebetween.

[0088] In some embodiments, the electrospun fibers of the present disclosure include one or more polymers, including hydrophilic polymers (as described herein), that provide various desirable properties, such as rheological properties suitable for electrospinning, physical properties (e.g., strength, flexibility, etc.) to provide a patch that is sufficiently to withstand handling during manufacture and use and is sufficiently flexible to conform to the shape of the mucosal surface, and a degree of hydrophilicity suitable for application to a mucosal surface. Such polymers may provide bioadhesive properties to aid in adhesion to the mucosal surface. In some embodiments, one or more additional polymers may be added to improve bioadhesion. In some embodiments, the bioadhesive is selected from the group consisting of dextran, polyethylene oxide (PEO), alginate, tragacanth, carrageenan, pectin, gelatin, guar, xanthan, gellan, methylcellulose, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose and their alkali salts, polymers of acrylic acid (PAA derivatives), chitosan, lectin, thiolated polymers, polyoxWSR, PAA-co-PEG (PEG is polyethylene glycol), and mixtures thereof. In some embodiments, the bioadhesive is PEO.

[0089] In some embodiments, the electrospun fibers of the present disclosure include polyvinylpyrrolidone and acrylic acid copolymers (e.g., Eudragit® copolymers) in combination with polyethylene oxide polymers. Such electrospun fiber compositions are described, for example, in U.S. Pat. No. 10,052,291, U.S. Patent Publication Nos. 2019 / 0254985, 2019 / 0254986, and 2019 / 0351662.

[0090] When polyvinylpyrrolidone is used as the polymer in the electrospun fibers, it is available in grades with molecular weights of approximately 2,500 Da to 3,000,000 Da. PVP can be purchased as Kollidon® with various molecular weight ranges as shown below. [Table 2]

[0091] Ethyl cellulose is sold under the trademark ETHOCEL™ (Dow Chemical Company) and is available in a variety of grades. Ethyl cellulose can have a variety of softening and melting point temperatures depending on its ethoxyl content. Ethyl cellulose is also produced in several different viscosities (see table below). [Table 3]

[0092] Acrylate and acrylic acid derivatives include polymethacrylates, methacrylate copolymers, acrylic acid copolymers, and methacrylate polymers, including the acrylates sold as EUDRAGIT, and the acrylate / octaacrylamide sold as DERMACRYL 79. Non-limiting examples of such acrylates include EUDRAGIT® E 12,5 (amino methacrylate copolymer), EUDRAGIT® E100 (amino methacrylate copolymer, basic butylated methacrylate copolymer), EUDRAGIT® E PO (amino methacrylate copolymer), EUDRAGIT® L 100-55, EUDRAGIT® L 100 (methacrylic acid-methyl methacrylate copolymer 1:1), EUDRAGIT® S 100 (methacrylic acid-methyl methacrylate copolymer 1:2), EUDRAGIT® RL 100, EUDRAGIT® RL 100 (ammonio methacrylate copolymer type A), EUDRAGIT® RL PO, EUDRAGIT® RS 100 (ammonio methacrylate copolymer type B), EUDRAGIT® RS PO. EUDRAGIT® E is a cationic polymer based on dimethylaminoethyl methacrylate and other neutral methacrylic acid esters, EUDRAGIT® L and S are methacrylic acid copolymers, which are the cationic copolymerization products of methacrylic acid and methyl methacrylate, and EUDRAGIT® RL or RS are ammonio methacrylate copolymers synthesized from acrylic acid and methacrylic acid.

[0093] Carboxymethyl cellulose is available in a wide selection of viscosity grades. In some embodiments, the viscosity of the carboxymethyl cellulose in the electrospun fibers ranges from 10 to 100,000 mPa. * In some embodiments, the carboxymethylcellulose is a sodium salt.

[0094] Methylcellulose is sold under the name METHOCEL™ (Dow Chemical Company) and is available in a wide range of viscosity grades. In some embodiments, the viscosity grade of the methylcellulose in the electrospun fibers is about 3 mPA. * From less than s to about 100,000 mPA * Up to s.

[0095] HPMC is sold under the names Methocel® and Klucel®. In some embodiments, the HPMC of the electrospun fibers has an average molecular weight of about 80,000 Da to about 140,000 Da.

[0096] In some embodiments, the polyvinyl alcohol has a molecular weight ranging from about 20,000 Da to about 200,000 Da. In some embodiments, the polyvinyl alcohol has a molecular weight ranging from about 100,000 Da to about 200,000 Da.

[0097] In some embodiments, polyethylene oxide (PEO) is used in grades having a molecular weight of approximately about 100,000 Da to about 7,000,000 Da. In some embodiments, polyethylene oxide (PEO) is used in grades having an average molecular weight of about 700,000 Da to about 4,000,000 Da. Polyethylene oxide is sold under the name POLYOX™ (Dow Chemical Company) and has a molecular weight range of about 100,000 Da to about 7,000,000 Da.

[0098] In some embodiments, the PEO has a molecular weight of about 100,000 Da to about 4,000,000 Da. In some embodiments, the PEO has a molecular weight of about 100,000 Da to about 700,000 Da. In some embodiments, the PEO has a molecular weight of about 100,000 Da to about 400,000 Da. In some embodiments, the PEO has a molecular weight of about 200,000 Da. In some embodiments, the PEO has a molecular weight of more than about 2,000,000 Da. In some embodiments, the PEO has a molecular weight of about 2,000,000 Da to about 7,000,000 Da.

[0099] In some embodiments, dextran is used in grades having a molecular weight of about 400,000 Da to about 2,000,000 Da. In some embodiments, dextran has a molecular weight of about 500,000 Da to about 2,000,000 Da, for example, about 700,000 Da to about 800,000 Da, or about 1,000,000 Da to about 2,000,000 Da.

[0100] In some embodiments, the one or more polymers are present in an amount ranging from about 30% to about 99.9% by weight of the electrospun fiber, such as about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99.9%, including all ranges and values ​​therebetween. In some embodiments, the one or more polymers are present in an amount ranging from about 50% to about 99.9% by weight of the electrospun fiber. In some embodiments, the one or more polymers are present in an amount ranging from about 75% to about 99.9% by weight of the electrospun fiber. In some embodiments, the one or more polymers are present in an amount ranging from about 75% to about 95% by weight of the electrospun fiber. In some embodiments, the one or more polymers are present in an amount ranging from about 75% to about 90% by weight of the electrospun fiber.

[0101] As disclosed herein, the electrospun fibers of the present disclosure include a therapeutically effective amount of an active agent. In some embodiments, the active agent is an anti-inflammatory agent and / or an immunosuppressant.

[0102] In some embodiments, the anti-inflammatory / immunosuppressant is a corticosteroid. In some embodiments, the corticosteroid is selected from the group consisting of amcinonide, betamethasone, budesonide, clobetasol, clobetasone, cortisone, desonide, desoxycortisone, desoxymethasone, dexamethasone, diflucortron, diflorasone, flucortisone, flumethasone, flunisolide, fluocinonide, fluocinolone, fluorometholone, fluprednisolone, flurandrenolide, fluticasone, halcinonide, halobetasol, hydrocortisone, meprednisone, methylprednisone, mometasone, paramethasone, prednicarbate, prednisone, prednisolone, and triamcinolone, or a pharma- ceutically acceptable ester or acetonide thereof. In some embodiments, the steroid is selected from the group consisting of betamethasone, budesonide, clobetasol, clobetasone, desoximetasone, diflucortron, diflorasone, fluocinonide, fluocinolone, halcinonide, halobetasol, hydrocortisone, mometasone, and triamcinolone, or a pharma- ceutically acceptable ester thereof. In some embodiments, the corticosteroid is selected from the group consisting of diflorasone diacetate, betamethasone dipropionate, mometasone furoate, and clobetasol propionate. In some embodiments, the corticosteroid is mometasone furoate.

[0103] In some embodiments, the anti-inflammatory agent is a nonsteroidal anti-inflammatory active drug (NSAID). In some embodiments, the NSAID is selected from the group consisting of diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.

[0104] In some embodiments, the immunosuppressant is a calcineurin inhibitor. In some embodiments, the calcineurin inhibitor is selected from the group consisting of tacrolimus, picrolimus, pimecrolimus, cyclosporine, or voclosporin. In some embodiments, the calcineurin inhibitor is selected from the group consisting of tacrolimus, picrolimus, and cyclosporine.

[0105] In some embodiments, the immunosuppressant is an interleukin inhibitor, a TNF-α inhibitor, or a selective immunosuppressant. In some embodiments, the interleukin inhibitor is rilonacept, secukinumab, ixekizumab, brodalumab, ustekinumab, risankizumab, guselkumab, or tildrakizumab. In some embodiments, the TNF-α inhibitor is etanercept or infliximab. In some embodiments, the immunosuppressant is pomalidomide, methotrexate, azathioprine, or lenalidomide.

[0106] In some embodiments, the electrospun fibers of the present disclosure include an anesthetic selected from the group consisting of local anesthetics (e.g., lidocaine, benzocaine, etc.), acetaminophen, nonsteroidal anti-inflammatory active drugs (NSAIDs), benzamide hydrochloride, etomidate, ketamine, propofol, gabapentin, tramadol, and pregabalin. In some embodiments, the anesthetic is selected from the group consisting of lidocaine, acetaminophen, nonsteroidal anti-inflammatory active drugs (NSAIDs, e.g., aspirin, naproxen, ibuprofen, diclofenac, etc.), etomidate, ketamine, propofol, gabapentin, tramadol, and pregabalin. In some embodiments, the NSAID is selected from the group consisting of diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin. In some embodiments, the NSAID is selected from the group consisting of aspirin, naproxen, ibuprofen, and diclofenac. In some embodiments, the anesthetic is a local anesthetic. In some embodiments, the anesthetic is selected from the group consisting of lidocaine, benzocaine, prilocaine, xylocaine, tetracaine, capsaicin, menthol, and methyl salicylate. In some embodiments, the anesthetic is lidocaine or articaine. In some embodiments, the anesthetic is lidocaine.

[0107] In some embodiments, the active agent is about 0.01% to about 15.0% (wt / wt%) of the electrospun fiber or fiber layer, including all ranges and values ​​therebetween, such as about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%. In some embodiments, the active agent is about 0.01% to about 10% (wt / wt%) of the electrospun fiber or fiber layer. In some embodiments, the active agent is about 0.01% to about 5.0% (wt / wt%) of the electrospun fiber or fiber layer. In some embodiments, the active agent is about 1% to about 10% (wt / wt%) of the electrospun fiber or fiber layer. In some embodiments, the active agent is about 1% to about 5.0% (wt / wt%) of the electrospun fiber or fiber layer.

[0108] In some embodiments, at least about 50% of the active agent disclosed herein is released from the electrospun fiber layer within about 120 minutes, about 90 minutes, about 60 minutes, or about 30 minutes after application of the patch to the target site. In some embodiments, at least about 50% of the active agent disclosed herein is released from the electrospun fiber layer within about 30 minutes after application. In some embodiments, complete or substantially complete (e.g., greater than 85%, greater than 90%, greater than 95%, or greater than 99%) release of the active agent from the electrospun fiber layer is achieved within about 2-3 hours after application.

[0109] The present disclosure contemplates electrospun fibers that combine any of the therapeutically active agents described herein with any of the polymers described above.

[0110] In some embodiments, the electrospun fibers further comprise a plasticizer. In some embodiments, the plasticizer of the present disclosure comprises any pharma- ceutically acceptable plasticizer known in the art that has favorable organoleptic properties, e.g., no odor or unpleasant taste.

[0111] In some embodiments, the plasticizer is a hydrophobic plasticizer. In some embodiments, the hydrophobic plasticizer is selected from the group consisting of acetyl triethyl citrate, tributyl citrate, triethyl citrate, castor oil, diacetylated monoglyceride, dibutyl sebacate, diethyl phthalate, triacetin, tributyrin, cellulose nitrate, or mixtures thereof. In some embodiments, the plasticizer is a hydrophilic plasticizer. In some embodiments, the hydrophilic plasticizer is selected from the group consisting of sorbitol, glycerol, polyethylene glycol (e.g., polyethylene glycol 1500), polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof.

[0112] In some embodiments, the plasticizer is a biodegradable polymer. In some embodiments, the biodegradable polymer is a polyester. In some embodiments, the biodegradable polymer is poly(lactic acid) or poly(lactide-co-glycolide).

[0113] In some embodiments, the plasticizer is a polymeric plasticizer, hi some embodiments, the polymeric plasticizer has a molecular weight of up to about 100,000 Da. In some embodiments, the polymeric plasticizer has a molecular weight of about 20,000 Da to about 100,000 Da, for example, about 20,000 Da, about 25,000 Da, about 30,000 Da, about 35,000 Da, about 40,000 Da, about 45,000 Da, about 50,000 Da, about 55,000 Da, about 60,000 Da, about 65,000 Da, about 70,000 Da, about 75,000 Da, about 80,000 Da, about 85,000 Da, about 90,000 Da, about 95,000 Da, or about 100,000 Da, including all ranges and values ​​therebetween. In some embodiments, the polymeric plasticizer has a molecular weight of about 100,000 Da to about 200,000 Da. In some embodiments, the polymeric plasticizer is polyethylene glycol, polyethylene glycol monomethyl ether, polyesteramide, poly(lactic acid), or poly(lactide-co-glycolide). In some embodiments, the polymeric plasticizer is polyethylene glycol, polyethylene glycol monomethyl ether, poly(lactic acid), or poly(lactide-co-glycolide). In some embodiments, the polymeric plasticizer is polyethylene glycol or polyethylene glycol monomethyl ether.

[0114] In some embodiments, the plasticizer is an oligomeric plasticizer. In some embodiments, the oligomeric plasticizer has a maximum of about 100 repeating units, a maximum of about 50 repeating units, a maximum of about 25 repeating units, or a maximum of about 10 repeating units. In some embodiments, the oligomeric plasticizer has about 10-100 repeating units.

[0115] In some embodiments, the plasticizer is a non-polymeric plasticizer.In some embodiments, the non-polymeric plasticizer is selected from the group consisting of citrate esters, fatty acid esters, sebacate esters, phthalate esters, and glycol derivatives.In some embodiments, the non-polymeric plasticizer is selected from the group consisting of triethyl citrate, acetyl triethyl citrate, tributyl citrate, butyl stearate, glycerol monostearate, stearyl alcohol, castor oil, mineral oil, diacetylated monoglyceride, dibutyl sebacate, diethyl phthalate, dibutyl phthalate, dioctyl phosphate, sorbitol, glycerol, triacetin, tributyrin, propylene glycol, or mixtures thereof.

[0116] In some embodiments, the plasticizer comprises a blend of two or more plasticizers. In some embodiments, the plasticizer comprises a blend of a polymeric plasticizer and a non-polymeric plasticizer. In some embodiments, the blend comprises a non-polymeric plasticizer disclosed herein and one or more polymers of the electrospun fibers disclosed herein. In some embodiments, the blend comprises one or more polymers selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl methylcellulose, and methacrylic acid copolymers plasticized with a non-polymeric plasticizer disclosed herein.

[0117] In some embodiments, the plasticizer is selected from the group consisting of citrate esters, fatty acid esters, sebacate esters, phthalate esters, and glycol derivatives.In some embodiments, the plasticizer is selected from the group consisting of triethyl citrate, acetyl triethyl citrate, tributyl citrate, butyl stearate, glycerol monostearate, stearyl alcohol, castor oil, mineral oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, dibutyl phthalate, dioctyl phosphate, sorbitol, glycerol, triacetin, tributyrin, cellulose nitrate, polyethylene glycol 1500, polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof.In some embodiments, the hydrophobic plasticizer is selected from the group consisting of acetyl triethyl citrate, tributyl citrate, triethyl citrate, castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, triacetin, tributyrin, cellulose nitrate, or mixtures thereof. In some embodiments, the hydrophilic plasticizer is selected from the group consisting of sorbitol, glycerol, polyethylene glycol, polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof, hi some embodiments, the plasticizer is dibutyl sebacate.

[0118] In some embodiments, the electrospun fibers include about 1% to about 30% by weight of plasticizer, such as about 1%, about 2.5%, about 5%, about 7.5%, about 10%, about 12.5%, about 15%, about 17.5%, about 20%, about 22.5%, about 25%, about 27.5%, or about 30%. In some embodiments, the electrospun fibers include about 2.5% to about 30% by weight of plasticizer. In some embodiments, the electrospun fibers include about 2.5% to about 25% by weight of plasticizer. In some embodiments, the electrospun fibers include about 5% to about 20% by weight of plasticizer. In some embodiments, the electrospun fibers include about 5% to about 10% by weight of plasticizer. In some embodiments, the electrospun fibers include about 10% by weight of plasticizer.

[0119] In some embodiments, the electrospun fibers of the present disclosure further comprise an absorption enhancer, which improves the absorption or penetration of the active agent through the skin or mucosa. In some embodiments, the presence of the absorption enhancer improves the sublingual absorption or penetration of the therapeutic active agent. In some embodiments, the presence of the absorption enhancer improves the oral mucosa absorption or penetration of the therapeutic active agent.

[0120] In some embodiments, the absorption enhancer is selected from the group consisting of fatty acids, non-ionic surfactants, polycations, thiolated polymers, cyclodextrins, and cell-penetrating peptides.

[0121] In some embodiments, the absorption enhancer is a fatty acid, hi some embodiments, the fatty acid is selected from the group consisting of caproic acid, caprylic acid, capric acid, sodium caprate, lauric acid, stearic acid, oleic acid, linoleic acid, and linolenic acid.

[0122] In some embodiments, the absorption enhancer is a non-ionic surfactant. In some embodiments, the non-ionic surfactant is selected from the group consisting of polysorbates (e.g., polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80), polyethylene glycol alkyl ethers (e.g., polyethylene glycol dodecyl ether, polyethylene glycol hexadecyl ether, polyethylene glycol octadecyl ether, and polyethylene glycol oleyl ether), polyoxyethylene alkyl ethers, (polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, and polyoxyethylene stearyl ether), nonylphenoxy polyoxyethylene (NPPOE), laurate sucrose ester (SE), and sodium glycocholate.

[0123] In some embodiments, the absorption enhancer is a polycation, hi some embodiments, the polycation is selected from the group consisting of chitosan and its quaternary ammonium derivatives, poly-L-arginine, aminated gelatin, and cetylpyridinium chloride.

[0124] In some embodiments, the absorption enhancer is a thiolated polymer.In some embodiments, the thiolated polymer is selected from the group consisting of carboxymethylcellulose-cysteine, polycarbophil (PCP)-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-thioethylamidine, chitosan iminothiolane, chitosan-glutathione conjugate, polyacrylic acid-cysteine, polymethacrylic acid-cysteine, and hyaluronic acid-L-cysteine.

[0125] In some embodiments, the absorption enhancer is a cyclodextrin, hi some embodiments, the cyclodextrin is selected from the group consisting of methylated β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and sulfobutylether-β-cyclodextrin.

[0126] In some embodiments, the absorption enhancer is a cell penetrating peptide. In some embodiments, the cell penetrating peptide is selected from the group consisting of penetratin, Tat (YGRKKKRRQRRR), R6, R8, R9, pVEC (LLIILRRRIRKQAHAHSK), RRL helix (RRLRRLLRRLRRLLRRLR), shuffle (RWFKIQMQIRRWKNKK), and penetramax (KWFKIQMQIRRWKNKR).

[0127] In some embodiments, the patch of the present disclosure delivers an effective amount of therapeutic active agent transdermally.Similar to oral active agent delivery, transdermal delivery has several advantages, including the ability to achieve steady-state active agent levels, bypass first-pass metabolism in the liver, increase patient compliance, and reduce adverse gastrointestinal (GI) effects.

[0128] In some embodiments, the efficiency of transdermal delivery is improved by adding an absorption enhancer (i.e., a penetration enhancer) as described herein. In some embodiments, the absorption enhancer is a fatty acid (e.g., oleic acid), a terpene, a surfactant, propylene glycol, a pyrrolidone derivative (e.g., N-methyl-2-pyrroldone), a carbamic acid derivative, a dioxolone derivative, and a dioxane derivative. In some embodiments, the absorption enhancer is a cell-penetrating peptide (e.g., penetratin), a skin-penetrating peptide (hyaluronic acid conjugated to a phospholipid), or an antimicrobial peptide (e.g., magainin, GIGKFLHSAKKFGKAFVG EIMNS). In some embodiments, the absorption enhancer comprises a nanocarrier, including, but not limited to, a liposome, a niosome, a transfersome, and an ethosome. Absorption enhancers relevant to the present disclosure include those described in B. Chaulagain et al. "Passive Delivery of Protein Drugs Through Transdermal Route" Artificial Cells, Nanomedicine, and Biotechnology 2018, 46, 5471-5487, which is incorporated by reference in its entirety.

[0129] In some embodiments, the efficiency of transdermal delivery is improved by applying heat to the skin, as described in S. Szunerits et al. "Heat: A Highly Efficient Skin Enhancer for Transdermal Drug Delivery" Front. Bioeng. Biotechnol. 2018, 6(15), 1-13, which is incorporated by reference in its entirety. For example, in some embodiments, heat-assisted microporation is used to create transport channels in the skin to improve the penetration of therapeutic active agents. In some embodiments, laser thermal ablation, based on selective removal of the stratum corneum (SC) by localized microsecond heat pulses, is used to increase the permeability of the skin's external barrier to therapeutic active agents.

[0130] In some embodiments, the patches of the present disclosure include an impermeable layer to prevent premature detachment from the treatment area, as well as to provide other therapeutic benefits.

[0131] In some embodiments, the impermeable layer is provided as a coating disposed over the active agent-containing layer, hi some embodiments, the impermeable layer is spun together with the active agent-containing layer and thus is integral with the electrospun fiber.

[0132] In some embodiments, the impermeable layer is a backing layer. In some embodiments, the impermeable layer is a hydrophobic impermeable layer.

[0133] In some embodiments, the impermeable layer protects the active agent-containing layer from moisture or saliva. In some embodiments, the impermeable layer protects the active agent layer from being washed away from the application site, which would reduce or eliminate the desired local therapeutic effect. In some embodiments, the impermeable layer functions as an occlusive layer, which drives the penetration of the active agent into the skin or mucosa.

[0134] In some embodiments, the impermeable layer comprises a hydrophobic polymer. In some embodiments, the hydrophobic polymer is selected from the group consisting of polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone) (PCL), carbosan, or polysoftan. In some embodiments, the hydrophobic polymer is PCL.

[0135] In some embodiments, the impermeable layer comprises one or more biodegradable polyesters. In some embodiments, the biodegradable polyesters are aliphatic polyesters. In some embodiments, the biodegradable polyesters are aromatic polyesters. In some embodiments, the impermeable layer comprises one or more polymers selected from the group consisting of poly(caprolactone), poly(glycolic acid), poly(lactic acid), poly(lactide-co-glycolide), poly(butylene succinate), poly(butylene succinate-co-adipate), poly(p-dioxane), and poly(trimethylene carbonate). In some embodiments, the impermeable layer comprises one or more polymers selected from the group consisting of poly(caprolactone), poly(glycolic acid), poly(lactic acid), and poly(lactide-co-glycolide). In some embodiments, the impermeable layer comprises poly(caprolactone).

[0136] In some embodiments, the impermeable layer comprises polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone), carbosan, or polysoftan. In some embodiments, the impermeable layer comprises acrylates / octylacrylamide copolymer (sold under the name DERMACRL® 79), amino methacrylate copolymer (EUDRAGIT®), dimethylaminoethyl methacrylate, methacrylate, methyl methacrylate (e.g., EUDRAGIT® E 100), or other acrylates.

[0137] In some embodiments, the impermeable layer comprises a plasticizer. In some embodiments, the plasticizer is a hydrophobic plasticizer disclosed herein. In some embodiments, the plasticizer is a hydrophilic plasticizer disclosed herein. In some embodiments, the plasticizer is a polymeric plasticizer disclosed herein. In some embodiments, the plasticizer is an oligomeric plasticizer disclosed herein. In some embodiments, the plasticizer is a non-polymeric plasticizer disclosed herein. In some embodiments, the plasticizer comprises a blend of two or more plasticizers. For example, in some embodiments, the plasticizer comprises a blend of a polymeric and a non-polymeric plasticizer. In some embodiments, the plasticizer is selected from the group consisting of citrate esters, fatty acid esters, sebacate esters, phthalate esters, and glycol derivatives. In some embodiments, the plasticizer is selected from the group consisting of triethyl citrate, acetyl triethyl citrate, tributyl citrate, butyl stearate, glycerol monostearate, stearyl alcohol, castor oil, mineral oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, dibutyl phthalate, dioctyl phosphate, sorbitol, glycerol, triacetin, tributyrin, cellulose nitrate, polyethylene glycol 1500, polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof. In some embodiments, the hydrophobic plasticizer is selected from the group consisting of acetyl triethyl citrate, tributyl citrate, triethyl citrate, castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, triacetin, tributyrin, cellulose nitrate, or mixtures thereof. In some embodiments, the hydrophilic plasticizer is selected from the group consisting of sorbitol, glycerol, polyethylene glycol, polyethylene glycol monomethyl ether, propylene glycol, or mixtures thereof, hi some embodiments, the plasticizer is dibutyl sebacate.

[0138] In some embodiments, the impermeable layer comprises about 1% to about 50% by weight of a plasticizer, such as about 1%, about 2.5%, about 5%, about 7.5%, about 10%, about 12.5%, about 15%, about 17.5%, about 20%, about 22.5%, about 25%, about 27.5%, about 30%, about 32.5%, about 35%, about 37.5%, about 40%, about 42.5%, about 45%, about 47.5%, or about 50%. In some embodiments, the impermeable layer comprises about 1% to about 35% by weight of a plasticizer. In some embodiments, the impermeable layer comprises about 2.5% to about 25% by weight of a plasticizer. In some embodiments, the impermeable layer comprises about 5% to about 20% by weight of a plasticizer. In some embodiments, the impermeable layer comprises about 5% to about 10% by weight of a plasticizer. In some embodiments, the impermeable layer comprises about 10% by weight of a plasticizer.

[0139] In some embodiments, the impermeable layer comprises about 5-70% by weight of the patch, for example, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% by weight of the patch, including all values ​​and ranges therebetween. In some embodiments, the impermeable layer comprises about 5-50% by weight of the patch. In some embodiments, the impermeable layer comprises about 10-30% by weight of the patch.

[0140] In some embodiments, the impermeable layer of the present disclosure has an areal density of less than about 100 grams per square meter (gsm), less than about 95 gsm, less than about 90 gsm, less than about 85 gsm, less than about 80 gsm, less than about 75 gsm, less than about 70 gsm, less than about 65 gsm, less than about 60 gsm, less than about 55 gsm, less than about 50 gsm, less than about 45 gsm, less than about 40 gsm, less than about 35 gsm, less than about 30 gsm, less than about 25 gsm, less than about 20 gsm, less than about 15 gsm, less than about 10 gsm, or less than about 5 gsm, including all ranges and values ​​therebetween. In some embodiments, the impermeable layer has an areal density of less than about 100 gsm. In some embodiments, the impermeable layer has an areal density of less than about 75 gsm. In some embodiments, the impermeable layer has an areal density of less than about 50 gsm. In some embodiments, the impermeable layer has an areal density of less than about 25 gsm. In some embodiments, the impermeable layer has an areal density of less than about 15 gsm. In some embodiments, the impermeable layer has an areal density of about 10 gsm to about 100 gsm. In some embodiments, the impermeable layer has an areal density of about 15 gsm to about 75 gsm. In some embodiments, the impermeable layer has an areal density of about 15 gsm to about 50 gsm. In some embodiments, the impermeable layer has an areal density of about 15 gsm to about 30 gsm. In some embodiments, the impermeable layer has an areal density of about 15 gsm to about 20 gsm. In some embodiments, the impermeable layer has an areal density of about 17 gsm. In some embodiments, the areal density of the impermeable layer is about the same as the electrospun fiber layer. In some embodiments, the reduced areal density of the impermeable layer results in increased flexibility of the patch. In some embodiments, the patch with increased flexibility is more comfortable after application to the treatment area of ​​a subject in need thereof. In some embodiments, a patch with increased flexibility adheres to the anogenital area for a longer period of time as compared to a patch with less flexibility.

[0141] In some embodiments, the present disclosure provides a method of treating a disease or condition in a patient in need thereof, the method comprising applying an active agent-containing patch disclosed herein to an affected area of ​​a patient in need thereof.

[0142] In some embodiments, the present disclosure provides a method for treating an inflammatory condition, an autoimmune disease, or cancer. In some embodiments, the present disclosure provides a method for treating an inflammatory condition. In some embodiments, the inflammatory condition is an inflammatory skin condition disclosed herein. In some embodiments, the inflammatory skin condition is a skin condition affecting the male or female genitalia. In some embodiments, the inflammatory condition is an inflammatory mucosal condition disclosed herein.

[0143] In some embodiments, the disease or condition is a disease or condition of the vulvar skin. In some embodiments, the disease or condition is selected from the group consisting of vulvar lichen sclerosus, vulvar lichen planus, vulvar psoriasis, vulvar skin disease, and vulvar lichen simplex chronicus. In some embodiments, the condition is vulvar lichen sclerosus. In some embodiments, the disease or condition is a disease or condition of the male genital skin. In some embodiments, the disease or condition is male genital lichen sclerosus. In some embodiments, the condition is lichen sclerosus of the glans penis.

[0144] In some embodiments, the disease or condition is selected from the group consisting of recurrent aphthous stomatitis, oral lichen planus, pemphigoid, pemphigus, oral mucositis, Behcet's disease, and Lipschutz ulcer.

[0145] In some embodiments, the affected area of ​​the patient is the anogenital area. In some embodiments, the affected area of ​​the patient is the male or female genitalia. In some embodiments, the affected area of ​​the patient is the vulva, glans penis, or perianal area. In some embodiments, the affected area of ​​the patient is the vulva. In some embodiments, the affected area of ​​the patient is the glans penis. In some embodiments, the affected area of ​​the patient is the perianal area. In some embodiments, the affected area of ​​the patient is the oral mucosa.

[0146] In some embodiments, the patch is applied to a vulvar lichen sclerosus (VLS) lesion on the vulva. In some embodiments, the patch is applied to a VLS lesion on the perineum. In some embodiments, the patch is applied to a lichen sclerosus lesion on the male genitalia. In some embodiments, the patch is applied to a lichen sclerosus lesion on the glans penis.

[0147] In some embodiments, the active agent-containing patch of the present disclosure is administered (i.e., applied) to the anogenital area of ​​the patient. In some embodiments, the active agent-containing patch of the present disclosure is administered (i.e., applied) to the vulva of the patient. In some embodiments, the active agent-containing patch of the present disclosure is administered (i.e., applied) to the glans penis of the patient. In some embodiments, the active agent-containing patch of the present disclosure is administered (i.e., applied) to the perianal area of ​​the patient.

[0148] In some embodiments, an active agent-containing patch of the present disclosure is administered (i.e., attached) to a mucosa of a patient. In some embodiments, the mucosa is the oral mucosa of a patient (i.e., transmucosal or transmucosal administration).

[0149] In some embodiments, a patch of the present disclosure is administered (i.e., applied) to a patient's anogenital area, mucous membrane, lesion (e.g., VLS lesion) or other affected area. The patch of the present disclosure provides protection to the affected area, thereby promoting the natural healing process, with or without an active agent.

[0150] The patch of the present disclosure may be administered, for example, by placing the patch on the anogenital surface requiring treatment with the active agent-containing electrospun fibrous layer contacting the surface. The patch may be applied by hand or with the use of an applicator.

[0151] The patch of the present disclosure may be administered, for example, by placing the patch on the oral mucosa requiring treatment with the active agent-containing electrospun fiber layer in contact with the surface. The patch may be applied by hand or with the use of an applicator.

[0152] In some embodiments, the patch of the present disclosure is administered once a day. In some embodiments, the patch is administered twice a day. In some embodiments, the patch is administered three times a day. In some embodiments, the patch is administered four times a day. In some embodiments, the patch is administered once a day for a period of about 1-8 weeks. In some embodiments, the patch is administered twice a day for a period of about 1-8 weeks. In some embodiments, the patch is administered three times a day for a period of about 1-8 weeks. In some embodiments, the patch is administered four times a day for a period of about 1-8 weeks. In some embodiments, the patch is administered once a day for a period of about 2-4 weeks. In some embodiments, the patch is administered twice a day for a period of about 2-4 weeks. In some embodiments, the patch is administered three times a day for a period of 2-4 weeks. In some embodiments, the patch is administered four times a day for a period of 2-4 weeks. In some embodiments, the patch is administered once a day for at least one month. In some embodiments, the patch is administered twice a day for at least one month. In some embodiments, the patch is administered three times a day for at least one month. In some embodiments, the patch is administered four times a day for at least one month. In some embodiments, the patch is administered once a day for at least one week. In some embodiments, the patch is administered twice a day for at least one week. In some embodiments, the patch is administered three times a day for at least one week. In some embodiments, the patch is administered four times a day for at least one week. In some embodiments, the patch is administered to the patient as needed.

[0153] In one aspect, the disclosure provides a method of preparing a patch as described herein, the method comprising the steps of: (a) combining a solvent with one or more polymers and an active agent of the disclosure to prepare an electrospun mixture; (b) electrospinning the electrospun mixture of step (a) to prepare an electrospun fiber; and (c) attaching an impermeable backing layer to the electrospun fiber of step (b).

[0154] In some embodiments, the conductivity of the electrospinning mixture in step (a) is from about 150 μS / cm to about 600 μS / cm, e.g., about 150 μS / cm, 175 μS / cm, 200 μS / cm, about 225 μS / cm, about 250 μS / cm, about 275 μS / cm, about 300 μS / cm, about 325 μS / cm, about 350 μS / cm, about 375 μS / cm, about 400 μS / cm, about 425 μS / cm, about 450 μS / cm, about 475 μS / cm, about 500 μS / cm, about 525 μS / cm, about 550 μS / cm, about 575 μS / cm, or about 600 μS / cm, including all ranges and values ​​therebetween. In some embodiments, the conductivity of the electrospinning mixture in step (a) is from about 150 μS / cm to about 300 μS / cm.

[0155] In some embodiments, the solvent in step (a) is an aqueous alcoholic solvent. In some embodiments, the aqueous alcoholic solvent comprises ethanol and water. In some embodiments, the aqueous alcoholic solvent comprises about 20% to about 97% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 40% to about 97% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 80% to about 97% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 50% to about 80% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 50% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 80% (vol / vol%) ethanol. In some embodiments, the aqueous alcoholic solvent comprises about 97% (vol / vol%) ethanol.

[0156] In some embodiments, the aqueous alcoholic solvent comprises a mixture of ethanol and 2% acetic acid in phosphate buffered saline. In some embodiments, the aqueous solvent comprises about 40% to about 80% ethanol, with the balance being 2% acetic acid in 20% phosphate buffered saline (PBS). In some embodiments, the aqueous solvent comprises about 80% ethanol and 2% acetic acid in about 20% phosphate buffered saline (PBS).

[0157] In some embodiments, the solvent in step (a) comprises a mixture of an alcohol and dichloromethane or chloroform. In some embodiments, the alcohol is ethanol, n-propanol, or n-butanol. In some embodiments, the alcohol is n-butanol. In some embodiments, the solvent in step (a) is a mixture of n-butanol and chloroform. In some embodiments, the alkyl chloride is chloroform. In some embodiments, the solvent in step (a) comprises a mixture of two solvents selected from the group consisting of dichloromethane, ethanol, isopropanol, and butanone. In some embodiments, the solvent in step (a) comprises n-butanol and chloroform.

[0158] In some embodiments, the electrospun fibers comprise one or more polymers selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, dextran, and gelatin.

[0159] In some embodiments, step (a) further comprises the addition of a plasticizer as disclosed herein.

[0160] In some embodiments, the backing layer in step (c) further comprises a plasticizer as disclosed herein. EXAMPLES

[0161] Example 1 Mometasone loading and release from electrospun fibers

[0162] Preparation of electrospun fibers

[0163] Electrospinning solutions with the compositions provided in Table 1 were prepared by dissolving appropriate amounts of PVP, Eudragit RS100, and PEO in a 50 wt% solution of pure ethanol and demineralized water. Mometasone furoate was dissolved in DMSO and added to the polymer solution as needed to reach the desired concentration. In the case of samples 3 and 4, 1.25 wt% dibutyl sebacate was also added. Electrospun fibers were then prepared from each of the four solutions as described in International Publication Nos. WO2015 / 189212, WO2017 / 085264, WO2018 / 133910, and WO2018 / 133909, U.S. Patent No. 10,052,291, and U.S. Publication Nos. 2019 / 0254985, 2019 / 0254986, and 2019 / 0351662, which are incorporated by reference in their entireties for all purposes.

[0164] Upon analysis, it was determined that the electrospun fibers of Samples 3 and 4 contained approximately 7.35% by weight of dibutyl sebacate plasticizer. [Table 1]

[0165] Encapsulation Efficiency

[0166] Release of mometasone from electrospun materials into methanol

[0167] Procedure: Approximately 5 cm from samples 1-4 2 of electrospun material into smaller pieces (approximately 0.5 cm 2, not exact) and weighed. The electrospun material pieces were then transferred to 4 mL scintillation vials and mixed with 2 mL of methanol. After approximately 20 hours of incubation at ambient temperature with end-over-end rotation, the amount of mometasone released was determined by LC-MS analysis. Each sample was tested in duplicate to obtain two results for each sample. For example, sample 1 was tested twice to obtain results numbered 1.1 and 1.2, sample 2 was tested twice to obtain results numbered 2.1 and 2.2, and so on.

[0168] Results: The determined total amount of mometasone recovered from the samples of electrospun material in methanol is summarized in Figure 1. For sample 1 (Rivelin 0.1%), amounts of 0.05% w / w and 0.06% w / w were recovered relative to the mass of electrospun material. For sample 2 (Rivelin 0.01%), 0.01% w / w of mometasone was recovered in both duplicate runs. For sample 3 (RivelinDS 0.1%), 0.05 and 0.07% w / w of mometasone were recovered in the two duplicate runs. For sample 4 (RivelinDS 0.01%), an amount of 0.01% w / w of mometasone was recovered in both duplicate runs.

[0169] Release of mometasone from electrospun materials into buffer solution

[0170] Steps: Approx. 10cm 2 of electrospun material into smaller pieces (approximately 0.5 cm 2 , not exact) and weighed. The electrospun material pieces were then transferred to 20 mL scintillation vials and mixed with 4 mL of phosphate buffered saline for 3 h. At t=10, 20, 30, 60, 120, and 180 min, 100 μL samples were taken and mixed with 100 μL of methanol before analysis by LC-MS. The taken sample volume was immediately replaced with 100 μL of blank phosphate buffered saline. All samples were tested in duplicate.

[0171] Figures 2A and 2B summarize the release of mometasone from samples of electrospun material over a 3 hour period in phosphate buffered saline. The data, providing the amount of mometasone released as a percentage of the patch weight (Figure 2A) and as a percentage of total mometasone (Figure 2B), show a higher release from Samples 1 and 3 (Figures 2A and 2B, top four rows). As shown in Figure 1, these samples contain a higher mometasone loading than Samples 2 and 4. Graphing the release data against the average mometasone loading shows a higher release from Sample 3 (Figure 2B, top two rows, 1.25% DS), followed by Sample 1 (Figure 2B, top three and four rows). The lowest release is observed from Sample 4 (Figure 2B, bottom two rows).

[0172] Study conclusions

[0173] Between 0.05-0.07% mometasone was recovered from electrospun materials initially loaded with 0.1 wt% (samples 1 and 3), while 0.01% mometasone was recovered from electrospun materials initially loaded with 0.01 wt%. Controlling for loading, mometasone release was higher from sample 3 (Rivelin-DS 0.1%), followed by sample 1 (Rivelin 0.1%). The lowest release was observed from sample 4 (Rivelin-DS 0.01%). Example 2

[0174] Evaluation of the flexibility of the composition

[0175] Objective: To determine whether electrospun materials incorporating a plasticizer (10% dibutyl sebacate) exhibit increased flexibility compared to formulations without the plasticizer.

[0176] The following electrospun compositions were prepared according to the methods referenced above and subjected to flexibility testing. [Table 4] 1 The two-layer composition was calendered.

[0177] Testing Procedure: Compositions A-D were analyzed using a Stable Micro Systems Texture Analyzer equipped with a three-point bending test rig. Six samples (7.5 x 2 cm) were cut from each electrospun composition and mounted lengthwise on the rig with supports spaced 1.2 cm apart. A normal force was applied to the sample by the top probe at a rate of 1 mm / s for a total time period of 2 seconds. The applied force during push and lift was recorded.

[0178] Results: Figures 3A and 3B show the average applied force recorded for six samples of each composition. For both Composition B and Composition D, the peak force (i.e., the force applied at maximum deformation at 2 seconds) was lower compared to the respective unmodified compositions without dibutyl sebacate. This suggests that modifying the monolayer and bilayer electrospun materials with plasticizers can produce patches with increased flexibility. Example 3

[0179] Open-label study

[0180] Introduction

[0181] Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin disease that commonly affects the anogenital area. Patients with VLS often experience symptoms such as itching and pain.

[0182] It manifests clinically as areas of atrophy, edema, fissures, erosions, and / or hypertrophic hyperkeratotic plaques. Initial treatment regimens consist of daily applications of topical corticosteroids. Irritation due to alterations in the microbiome and mechanical shear are thought to influence disease severity.

[0183] We developed an adhesive patch (PVP / RS100 / PEO electrospun fibers and a PCL backing layer) that forms a protective barrier over the VLS lesion, thereby potentially contributing to pain relief.

[0184] Purpose of the test

[0185] This study was conducted to explore the adhesion and tolerability of a plain patch (containing no drug) when applied directly to a VLS lesion.

[0186] material and method

[0187] The composition of the bilayer adhesive patch used in this study was as follows: electrospun fiber layer: 21% PVP, 26% RS100, and 42% PEO, respectively, by weight of the patch; and · Impermeable layer: 10% PCL by weight of the patch.

[0188] Eligible subjects for the open-label study were women (aged 18 years or older) who were diagnosed with VLS and signed informed consent. Patients who were pregnant or menstruating at the time of patch application were excluded.

[0189] The primary endpoint was patch application and adhesion for at least 30 minutes. Secondary endpoints were the frequency and intensity of adverse events collected during the study, the subjects' ability to apply the patch correctly, and comprehension of the "instructions for use" leaflet.

[0190] Visual analog scales (VAS) were used for discomfort, pain, itching, and burning at baseline, 2 hours after application (or upon patch removal), and on day 2 (VAS 0-10, where 0 = no symptoms and 10 = worst possible). Concurrently, a physical examination was performed to grade redness, erosion, and edema (grades 0 (no symptoms) to 4 (maximum)). Ten questions regarding comfort, adhesion, and willingness to wear the medicated patch were administered on day 2.

[0191] result

[0192] Twelve VLS patients, ages 24-61 years (mean 55.1 years), were included. The majority had VLS for more than 1 year (<1 year (8.3%, n=1), 1-5 years (50%, n=6), 6-10 years (8.3%, n=1), >10 years (8.3%, n=1), NA (25%, n=3)). Baseline VLS symptoms as scored on a visual analog scale (VAS) were as follows: pain (mean 2.6, range 0-7), pruritus (mean 3.8, range 0-10), burning sensation (mean 3.3, range 0-8), and discomfort (mean 4.1, range 0-8).

[0193] All patients were able to apply the plain patch. Mean adhesion time was 9.5 hours on day 1 and 10.0 hours on day 2. No AEs were reported. All subjects were able to apply the patch correctly and follow the leaflet instructions.

[0194] The VAS scores of measured VLS symptoms (discomfort, pain, itching, and burning) were lower 2 hours after application and on the second day compared to baseline. Additionally, for both redness, erosion, and edema, all subjects (except 1) had a score of 0 or 1 on both days 1 and 2. For physical examination of the mucous membranes and skin (vulva and anal area), 5 subjects (41.6%) had a transition from abnormal to normal for either the skin or mucous membranes, or both, while for the remaining subjects (58.3%), no changes were reported. The overall response to the patch design was that they were easy and quick to apply.

[0195] conclusion

[0196] The first objective of studying the duration of application of the plain patch to the VLS lesions was achieved, as all subjects reported successful application, including a mean application time of more than 9 hours in both morning and evening. For all VLS symptoms, the VAS scores were lower after patch application compared to before application, indicating that the level of VLS symptoms after patch use was reduced as assessed by the subjects. No safety issues were reported, and the patch was well tolerated when applied to sensitive VLS lesions.

Claims

1. (a) one or more polymers, and A therapeutically effective amount of an active agent an electrospun fiber layer comprising electrospun fibers comprising (b) Impermeable layer A patch for treating a disease or condition of the vulva comprising: wherein after application to a patient in need thereof, the patch provides a therapeutically effective amount of the active agent for at least about 2 hours, and wherein the stiffness of the patch is from about 250 mN / mm to about 450 mN / mm as determined by a three-point bending test.

2. The patch of claim 1 , wherein at least one of the electrospun fibers and the impermeable layer further comprises a plasticizer.

3. The patch of claim 1 , wherein the electrospun fiber further comprises a plasticizer.

4. The patch of claim 1 , wherein the impermeable layer comprises a plasticizer.

5. The patch according to claim 2 , wherein the plasticizer is a hydrophobic plasticizer.

6. The patch according to claim 2 , wherein the plasticizer is a hydrophilic plasticizer.

7. The patch of any one of claims 2 to 6, wherein the plasticizer is a polymeric plasticizer.

8. The patch of any one of claims 2 to 6, wherein the plasticizer is an oligomeric plasticizer.

9. The patch of any one of claims 2 to 8, wherein the plasticizer comprises a blend of two or more plasticizers.

10. The patch according to any one of claims 2 to 4, wherein the plasticizer is selected from the group consisting of citrate esters, fatty acid esters, sebacate esters, phthalate esters, and glycol derivatives.

11. 5. The patch of any one of claims 2 to 4, wherein the plasticizer is selected from the group consisting of triethyl citrate, acetyl triethyl citrate, tributyl citrate, butyl stearate, glycerol monostearate, stearyl alcohol, castor oil, mineral oil, diacetylated monoglyceride, dibutyl sebacate, diethyl phthalate, dibutyl phthalate, dioctyl phosphate, sorbitol, glycerol, triacetin, tributyrin, cellulose nitrate, polyethylene glycol 1500, polyethylene glycol monomethyl ether, propylene glycol, or a mixture thereof.

12. 6. The patch of claim 5, wherein the hydrophobic plasticizer is selected from the group consisting of acetyl triethyl citrate, tributyl citrate, triethyl citrate, castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, triacetin, tributyrin, cellulose nitrate, or a mixture thereof.

13. 7. The patch of claim 6, wherein the hydrophilic plasticizer is selected from the group consisting of sorbitol, glycerol, polyethylene glycol, polyethylene glycol monomethyl ether, propylene glycol, or a mixture thereof.

14. A patch according to any one of claims 2 to 4, wherein the plasticizer is dibutyl sebacate.

15. The patch of any one of claims 2 to 14, wherein the plasticizer is present in an amount ranging from about 1.0% to about 35% by weight of the patch.

16. The patch of claim 2 or 3, wherein the electrospun fibers comprise from about 1% to about 30% by weight of a plasticizer.

17. The patch of claim 3 or 4, wherein the impermeable layer comprises from about 1% to about 50% by weight of a plasticizer.

18. The patch of any one of claims 1 to 17, wherein the one or more polymers comprise a hydrophilic polymer, a hydrophobic polymer, or a mixture thereof.

19. 19. The patch of any one of claims 1 to 18, wherein the one or more polymers are selected from the group consisting of polyvinylpyrrolidone, ammonio methacrylate copolymer, polyethylene glycol, polyethylene oxide, polyacrylate, sodium polyacrylate, polyvinyl alcohol, dextran, and gelatin.

20. the one or more polymers being (a) polyvinylpyrrolidone and ammonio methacrylate copolymer; (b) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene glycol; (c) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyethylene oxide; (d) polyvinylpyrrolidone, ammonio methacrylate copolymer, and dextran; (e) polyvinylpyrrolidone and gelatin, (f) polyvinylpyrrolidone, ammonio methacrylate copolymer, and gelatin; (g) polyvinylpyrrolidone and polyacrylates; (h) polyvinylpyrrolidone and sodium polyacrylate; (i) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyacrylate; (j) polyvinylpyrrolidone, ammonio methacrylate copolymer, and sodium polyacrylate; (k) polyvinylpyrrolidone and polyvinyl alcohol; (l) polyvinylpyrrolidone and polyethylene glycol, (m) polyvinylpyrrolidone, ammonio methacrylate copolymer, and polyvinyl alcohol; (n) polyvinylpyrrolidone and polyethylene oxide, or (o) Polyvinylpyrrolidone and dextran 20. The patch of any one of claims 1 to 19, comprising:

21. 21. The patch of any one of claims 1 to 20, wherein the one or more polymers are selected from the group consisting of polyvinylpyrrolidone (PVP), acrylates and acrylic acid copolymers, and mixtures thereof.

22. 22. The patch of any one of claims 1 to 21, wherein the one or more polymers are polyvinylpyrrolidone (PVP), ammonio methacrylate copolymer type B, or a mixture thereof.

23. 23. The patch of claim 22, wherein the weight ratio of polyvinylpyrrolidone to ammonio methacrylate copolymer is from about 0.8 to about 2.

24. The patch of any one of claims 1 to 18, wherein the one or more polymers are selected from the group consisting of polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone) (PCL), carbosan, or polysoftan.

25. The patch of any one of claims 1 to 24, wherein the impermeable layer comprises a hydrophobic polymer.

26. 26. The patch of claim 25, wherein the hydrophobic polymer is selected from the group consisting of polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone) (PCL), carbosan, or polysoftane.

27. The patch of claim 25 or 26, wherein the hydrophobic polymer is PCL.

28. 28. The patch of any one of claims 21 to 27, wherein the electrospun fiber layer further comprises a bioadhesive material.

29. 29. The patch of any one of claims 21 to 28, wherein the bioadhesive material is selected from the group consisting of dextran, polyethylene oxide (PEO), alginate, tragacanth, carrageenan, pectin, gelatin, guar, xanthan, gellan, methylcellulose, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose and its alkali salts, polymers of acrylic acid (PAA derivatives), chitosan, lectin, thiolated polymers, Polyox WSRA, PAA-co-PEG (PEG is polyethylene glycol), and mixtures thereof.

30. 30. The patch of any one of claims 21 to 29, wherein the bioadhesive material is PEO.

31. The patch of any one of claims 1 to 30, wherein the weight ratio of PVP:ammonio methacrylate copolymer B:PEO is from about 2:1:1 to about 2:2.5:

4.

32. 32. The patch of any one of claims 1 to 31, wherein the average thickness of the patch prior to application is less than about 0.6 mm.

33. 32. The patch of any one of claims 1 to 31, wherein the average thickness of the patch prior to application is less than about 0.3 mm.

34. 32. The patch of any one of the preceding claims, wherein the electrospun fiber layer has an areal density of less than about 125 grams per square meter (gsm).

35. 32. The patch of any one of the preceding claims, wherein the electrospun fiber layer has an areal density of less than about 75 gsm.

36. The patch of any one of claims 1 to 31, wherein the electrospun fiber layer has an areal density of from about 15 gsm to about 75 gsm.

37. 37. The patch of any one of claims 1-36, wherein the electrospun fiber layer has a greater areal density than the impermeable layer.

38. 38. The patch of any one of claims 1 to 37, which is semicircular.

39. 39. The patch of any one of claims 1 to 38, wherein the vulvar disease or condition is selected from the group consisting of vulvar lichen sclerosus, vulvar lichen planus, vulvar psoriasis, vulvar skin disease, and vulvar lichen simplex chronicus.

40. 40. The patch of any one of claims 1 to 39, wherein the vulvar disease or condition is vulvar lichen sclerosus.

41. 41. The patch of any one of claims 1 to 40, wherein the active agent is an anti-inflammatory or immunosuppressant agent.

42. 42. The patch of any one of claims 1 to 41, wherein the anti-inflammatory / immunosuppressant is a corticosteroid.

43. 43. The patch of claim 42, wherein the corticosteroid is selected from the group consisting of diflorasone diacetate, betamethasone dipropionate, mometasone furoate, and clobetasol propionate.

44. 43. The patch of claim 42, wherein the corticosteroid is mometasone furoate.

45. 42. The patch of any one of claims 1 to 41, wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory active drug (NSAID).

46. 46. ​​The patch of claim 45, wherein the NSAID is selected from the group consisting of diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.

47. The patch of any one of claims 1 to 41, wherein the immunosuppressant is a calcineurin inhibitor.

48. The patch of claim 47, wherein the calcineurin inhibitor is cyclosporine, tacrolimus, or pimecrolimus.

49. The patch of any one of claims 1 to 41, wherein the immunosuppressant is an interleukin inhibitor, a TNF-α inhibitor, or a selective immunosuppressant.

50. 42. The patch of any one of claims 1 to 41, wherein the immunosuppressant is pomalidomide, methotrexate, azathioprine, or lenalidomide.

51. 51. The patch of any one of claims 1-50, wherein at least about 50% of the active agent is released from the electrospun fibrous layer within about 30 minutes after application.

52. The patch of any one of claims 1 to 50, wherein complete active agent release from the electrospun fiber layer is achieved in about 2 to 3 hours after application.

53. The electrospun fiber is (a) an active agent that treats a vulvar condition; (b) one or more hydrophilic polymers; (c) a bioadhesive material, and (d) optionally a plasticizer; (a) a hydrophobic polymer, and (b) Plasticizer as required a hydrophobic layer comprising the patch provides a therapeutically effective amount of an active agent for treating a vulvar condition for at least about two hours after application to the vulvar lesion; and 10. The patch of claim 1, wherein the stiffness of the patch is from about 250 mN / mm to about 450 mN / mm as determined by a three-point bending test.

54. 54. The patch of claim 53, wherein the hydrophobic layer comprises a plasticizer.

55. 55. The patch of any one of claims 53 to 54, wherein the hydrophobic layer comprises about 5% to about 50% by weight of a plasticizer.

56. 56. The patch of any one of claims 53 to 55, wherein the electrospun fibers comprise a plasticizer.

57. 57. The patch of any one of claims 53-56, wherein the electrospun fibers comprise from about 5% to about 50% by weight of a plasticizer.

58. 58. The patch of any one of claims 53 to 57, wherein the plasticizer is selected from the group consisting of acetyl triethyl citrate, tributyl citrate, triethyl citrate, castor oil, diacetylated monoglyceride, dibutyl sebacate, diethyl phthalate, sorbitol, glycerol, triacetin, tributyrin, cellulose nitrate, polyethylene glycol 1500, polyethylene glycol monomethyl ether, propylene glycol, or a mixture thereof.

59. 59. The patch of any one of claims 53 to 58, wherein the plasticizer is dibutyl sebacate.

60. 60. The patch of any one of claims 53-59, wherein the bioadhesive material is selected from the group consisting of dextran, polyethylene oxide, alginate, tragacanth, carrageenan, pectin, gelatin, guar, xanthan, gellan, methylcellulose, hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose and its alkali salts, polymers of acrylic acid (PAA derivatives), chitosan, lectin, thiolated polymers, Polyox WSRA, PAA-co-PEG (PEG is polyethylene glycol), and mixtures thereof.

61. 61. The patch of any one of claims 53 to 60, wherein the bioadhesive material is polyethylene oxide.

62. 62. The patch of any one of claims 53 to 61, wherein the hydrophilic polymer is selected from the group consisting of polyvinylpyrrolidone (PVP), acrylates and acrylic acid copolymers, and mixtures thereof.

63. 63. The patch of any one of claims 53 to 62, wherein the hydrophilic polymer is polyvinylpyrrolidone, ammonio methacrylate copolymer type B, or a mixture thereof.

64. 64. The patch of any one of claims 53 to 63, wherein the hydrophobic polymer is selected from the group consisting of polyethylene-co-vinyl acetate, ethyl cellulose, poly(caprolactone) (PCL), carbosan, or polysoftane.

65. 65. The patch of any one of claims 53 to 64, wherein the hydrophobic polymer is PCL.

66. 66. The patch of any one of claims 53 to 65, wherein the active agent treating the vulvar condition is a corticosteroid, an immunosuppressant, and / or an anti-inflammatory active agent.

67. 67. The patch of claim 66, wherein the active agent treating the vulvar condition is a corticosteroid / immunosuppressant selected from the group consisting of diflorasone diacetate, betamethasone dipropionate, mometasone furoate, and clobetasol propionate.

68. 67. The patch of claim 66, wherein the active agent treating the vulvar condition is a corticosteroid / immunosuppressant selected from the group consisting of pimecrolimus and tacrolimus.

69. the hydrophilic polymer comprises polyvinylpyrrolidone and ammonio methacrylate copolymer type B; the bioadhesive material is PEO; the hydrophobic polymer is PCL, and The plasticizer is dibutyl sebacate.

69. A patch according to any one of claims 53 to 68.

70. 70. A method for treating lichen sclerosus in a patient in need thereof, comprising the step of applying a patch according to any one of claims 1 to 69 to a lesion on a patient in need thereof.

71. 71. The method of claim 70, wherein the lichen sclerosus is vulvar lichen sclerosus or penile lichen sclerosus.

72. 72. The method of claim 70 or 71, wherein the patch is applied once per day, twice per day, three times per day, or four times per day.

73. 73. The method of any one of claims 70 to 72, wherein the patch is applied to a VLS lesion on the vulva.

74. 73. The method of any one of claims 70 to 72, wherein the patch is applied to the perineum VLS lesion.

75. 73. The method of any one of claims 70 to 72, wherein the patch is applied to a lesion on the glans penis.